Gaming company Konami will cough up $35.9 million dollars to rival company Aristocrat Technologies next year, eight years after a judge found that it had violated Aristocrat’s patent for a slot machine with an improved jackpot feature.
Gaming company Konami Australia has been ordered to pay rival Aristocrat Technologies a proportion of profits from the sale of patent-infringing poker machines over a 12-year period, as well as a chunk of damages for supply of the games that generated no revenue at all.
Trial in the battle of the buns has begun, with McDonald’s laying out a case for why its rival’s Big Jack burger infringes its trade mark, and Hungry Jack’s firing back that consumers could not confuse its flame-grilled meal with the iconic Big Mac.
Mineral exploration company Boart Longyear has been granted leave to appeal a finding that it infringed a patent for a mining tool, but it can’t avoid a recall of its tools, with a judge saying its actions were “not uninformed or innocent”.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.
A judge has found mining tool company Globaltech and mineral exploration company Boart Longyear infringed a patent for a mining tool owned by Australian Mud Company.
A judge has thrown out competing appeals of a decision finding Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Gaming giant Aristocrat Technologies has lost its legal challenge to a decision that rejected a patent for its popular Lightning Link electronic poker machine, after six High Court Justices were equally split on whether it could be patented.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.